A first step to a Parkinson treatment with stem cells.
The first clinical trial conducted in China (see HERE) to treat Parkinson’s disease and age-related macular degeneration and the second most common neurodegenerative disorder is to be launched shortly. In the next few months, surgeons from the city of Zhengzhou have planned to conduct a clinical trial to inject neurons derived from human stem cells into the brain of patients with Parkinson’s disease. This trial would be the first in the world to treat this disease with stem cells obtained from human embryos. Some researchers who work on Parkinson’s disease, however, worry that the trials might be misguided. In a second trial, a different team from the same city also hopes to use cells derived from human embryonic stem cells to treat age-related macular degeneration. Both experiments will be the first conducted in China since these practices were regulated in 2015. From an ethical point of view, it should be highlighted that both trials start from the use of human embryonic stem cells, with the difficulties that this entails, because it must not be forgotten that human embryos have to be destroyed to obtain them, which ethically cannot be justified from any point of view.
La entrada New clinical celular trial for treatment of Parkinson’s disease injecting stemcells in the patient brain aparece primero en Bioethics Observatory.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.